OPKO Health (LTS:0KCS) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0KCS OPKO Health Inc LTS:0KCS
57 GF Score
Price $1.21
GF Value $1.06
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is OPKO Health Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

LTS:0KCS
57GF Score
OPKO Health Inc LTS:0KCS
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is OPKO Health (LTS:0KCS) Overvalued in 2026?

Based on GuruFocus' analysis, OPKO Health stock appears to be overvalued. The current stock price of $1.21 is trading 14.2% above its estimated GF Value™ of $1.06. GuruFocus considers OPKO Health to be Modestly Overvalued.

Key valuation signals for LTS:0KCS:

  • Dividends Received:
  • GF Value™: $1.06 vs. price of $1.21 (14.2% above fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the LTS:0KCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


OPKO Health Business Description

Address 4400 Biscayne Boulevard, Miami, FL, USA, 33137
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
57GF Score

Get the complete analysis for LTS:0KCS

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.21
Price
$1.06
GF Value